First Trade Date for Gilead Sciences, Inc.
| Company Name | First Trade Date (yyyy-mm-dd) |
| Gilead Sciences, Inc. | 1992-01-22 |
| Company Name | Symbol |
| Gilead Sciences, Inc. | GILD |
| History and Business of Company (this information may include date of incorporation) | |
|
Gilead Sciences (GILD) is an independent biopharmaceutical concern that manufactures and commercializes proprietary therapeutics for challenging infectious diseases (viral, fungal, and bacterial diseases) and cancer. GILD also has expertise in liposomal drug delivery technology, a technology used to develop drugs that are safer, easier for patients to tolerate and more effective. The company's first product (launched in 1996) was Vistide (cidofovir injection), a treatment for cytomegalovirus (CMV) retinitis in patients with AIDS. GILD markets Vistide in the U.S.; outside the U.S., the drug is sold through a partnership with Pharmacia in all 15 countries of the European Union and several other countries worldwide. As of Mar. 31, 2001, GILD had four products on the market- AmBisome (amphotericin B) liposome formulation, an antifungal agent; DaunoXome (daunorubicin citrate liposome injection), a drug approved for the treatment of Kaposi's Sarcoma; VISTIDE (cidofovir injection) for the treatment of cytomegalovirus ('CMV') retinitis; and Tamiflu (oseltamivir phosphate) marketed by Hoffmann-LaRoche for the treatment of influenza, under a collaborative agreement. The company also has products to treat diseases caused by human immunodeficiency virus ('HIV'), hepatitis B virus, bacterial infections and cancer in its product development pipeline. AmBisome (81% of total revenues in 1999), is a liposomal formulation of amphotericin B, a powerful antifungal agent well known for its ability to attack and kill a broad variety of life- threatening fungal infections. Amphotericin B, however, has serious side effects, including kidney toxicity. Studies have shown that Amphotericin B delivered through GILD's proprietary liposomal formulation reduces the severity of its side effects. GILD markets AmBisome in 42 countries world. Tamiflu is an orally administered pill for the treatment of influenza A and B that was approved by the FDA on October 27, 1999. Tamiflu is in a new class of drugs called neuraminidase inhibitors that act by disabling all common strains of the flu virus and preventing the virus from spreading in a patient. Hoffman-La Roche, a co-developer of Tamiflu with GILD, holds the exclusive right to market Tamiflu. In early May 2001, GILD submitted a New Drug Application with the U.S. Food and Drug Administration and a Marketing Authorisation Application to the European Agency for approval to market tenofovir DF to treat patients with HIV. At year-end 2000, adefovir dipivoxil was in late-stage human clinical trials to treat patients with hepatitis B. INCORPORATED in Delaware June 22, 1987. OFFICE- 333 Lakeside Drive, Foster City, CA 94404 (Tel.: 650-574-3000). Fax - 650-522- 5853. WEBSITE-http://www.gilead.com. | |
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
© 1999-2004 by Magi Astrologers Worldwide Corporation. All Rights Reserved.